Hengdi Pharmaceutical: Shareholder Lei Xiaoyan has reduced holdings by 0.998%.

Hengdi Pharmaceutical announced that shareholder Lei Xiaoyan reduced 4.1671 million shares through centralized bidding from November 18, 2025 to February 17, 2026, with an average price of 14.25 yuan per share, accounting for 0.998% of the total share capital of the company. After the reduction, the shareholding decreased to 11.4929 million shares, accounting for 2.752%, compared to 15.66 million shares, accounting for 3.75% before. The source of the reduction this time is all shares issued before the company's initial public offering of stocks. The reduction plan has expired and complies with relevant regulations.